JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 77 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $1,260,000 | -20.2% | 254,590 | 0.0% | 0.04% | -21.7% |
Q1 2019 | $1,578,000 | +82.6% | 254,590 | -0.7% | 0.05% | +31.4% |
Q4 2018 | $864,000 | -68.8% | 256,473 | -39.7% | 0.04% | -58.8% |
Q3 2018 | $2,765,000 | -70.3% | 425,415 | -65.0% | 0.08% | -73.1% |
Q2 2018 | $9,304,000 | -64.8% | 1,214,593 | +2.7% | 0.32% | -69.0% |
Q1 2018 | $26,426,000 | +111.4% | 1,182,393 | +20.6% | 1.02% | +87.8% |
Q4 2017 | $12,500,000 | -16.0% | 980,393 | +2.6% | 0.54% | -26.0% |
Q3 2017 | $14,888,000 | -6.8% | 955,598 | -16.1% | 0.73% | -24.5% |
Q2 2017 | $15,971,000 | -29.1% | 1,138,370 | +2.2% | 0.97% | -33.5% |
Q1 2017 | $22,523,000 | – | 1,114,160 | – | 1.46% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |